Alphabet Inc. Class C (GOOGL.US) has taken the first step towards "non-invasive blood glucose monitoring": the Pixel Watch 5 is equipped with an insulin resistance tracking feature.

In the current market for wearable devices, which is caught in the spiral of hardware parameters, Alphabet Inc. Class C (GOOGL.US) has chosen a differentiated pathredefining the boundaries of health monitoring using AI. On August 12 local time, Alphabet Inc. Class C officially launched the Pixel Watch 5 smart watch at the Made by Google event in New York. Among the "Health Guardian" feature suite that comes with it, a new function for tracking insulin resistance trends became the focal point of the event. This marks the first time a consumer technology company has enabled long-term tracking of insulin resistance, a key metabolic indicator, in a wearable device, signifying a critical shift in the industry from "passively recording health data" to "actively warning of health risks." Technical Breakthrough: How Does AI "See" Insulin Resistance Without Needles or Blood? Unlike traditional blood glucose monitoring, Alphabet Inc. Class C's insulin resistance tracking feature does not directly measure or display blood glucose levels. Its technical approach involves integrating data from various built-in multimodal sensors in the smartwatch, including an accelerometer, barometer, heart rate sensor, and skin temperature sensor, and analyzing this data using an AI large model to assess the "burden level" the body faces when metabolizing food. Francis Ho, the product lead for Pixel Watch at Alphabet Inc. Class C, stated that the goal of this feature is to help users identify the "invisible stress" their bodies endure, rather than to provide diagnosis or treatment. According to Alphabet Inc. Class C, the development of this feature is based on training data from over 100,000 people, analyzing signals such as sleep, heart rate, and physical activity over time to identify long-term trends in insulin resistance. Users will receive their first detailed monthly summary report one month after wearing the watch, which will "reveal changes in metabolism, respiration, and cardiovascular systems early on." When the Google Health app detects a potential change in the user's insulin resistance level, it will send a notification, allowing users to consider adjusting their lifestyle or consulting a doctor. Three Major "Health Guardian" Features Launched: From Respiratory Emergencies to Blood Pressure Trends In addition to tracking insulin resistance, Alphabet Inc. Class C also introduced several groundbreaking health features, all unified under the "Health Guardian" suite: The emergency respiratory detection function is an industry first. The watch can continuously monitor for severe and sustained drops in blood oxygen through multimodal sensors and on-device AI; if a respiratory emergency is detected and the user becomes unresponsive, the watch can automatically call emergency services and send location information. This feature will first be launched in Europe. Blood pressure trend tracking generates a monthly report on blood pressure changes by analyzing pulse and activity patterns. This feature has been trained on data from over 500,000 individuals. Sleep respiratory quality monitoring can track blood oxygen changes every minute and offers new sleep surface and "smart wake" functions. The features for tracking insulin resistance, blood pressure trends, and sleep respiratory quality will first be available on the Pixel Watch 5 and Fitbit Air, and will later expand to older models such as the Pixel Watch 3 and 4. Hardware Upgrades and Pricing Strategy: AI-Driven "Integrated Software and Hardware" The Pixel Watch 5 is equipped with the Qualcomm Snapdragon W5 Gen 2 processor, with 50% more memory, a 12% improvement in CPU performance, and a 20% overall speed increase, further integrating Gemini AI capabilities. The starting price for the 41mm Wi-Fi version is $399, while the 45mm version is priced at $429. Battery life supports up to 40 hours. It will officially be on sale starting August 20. Strategic Depth: Alphabet Inc. Class C's Ambition for a "Health Ecosystem" The launch of the insulin resistance tracking feature is just one part of Alphabet Inc. Class C's health strategy. Earlier this week, Alphabet Inc. Class C announced the integration of analysis results from Abbott Laboratories' Lingo continuous glucose monitoring device into Google Health, showing how daily habits affect the body. Users can also connect their continuous glucose monitoring devices through the Health Connect app. This layout places Alphabet Inc. Class C in a unique strategic position: collecting foundational health data through its own hardware (Pixel Watch + Fitbit), generating actionable insights through AI models, and integrating third-party professional medical device data through an open ecosystem (Health Connect)forming a complete closed-loop from data collection, analysis to intervention. From an industry perspective, several tech companies are exploring glucose tracking functionalities. Whoop is investigating how to access data from glucose monitoring devices; smart ring company Oura received a $75 million investment from Dexcom in 2024; and Apple Inc. has also tested a glucose application aimed at pre-diabetic populations. However, Alphabet Inc. Class C is the first company to integrate insulin resistance tracking directly into consumer-grade wearable devices. Market Insights: A Valuation Reconstruction from "Fitness Tools" to "Health Infrastructure" For investors, the strategic significance of Alphabet Inc. Class C's recent launch far exceeds that of just a new hardware upgrade. The wearable device market has long faced homogenization challengesheart rate, blood oxygen, and sleep monitoring have become standard features, and marginal improvements in hardware parameters are unlikely to drive a new wave of growth. The tracking of insulin resistance represents a new dimension of differentiation: it upgrades wearable devices from "tools for fitness enthusiasts" to "infrastructure for universal health management." In terms of market size, there are billions of people globally with pre-diabetes, and insulin resistance is the core pathological mechanism for this population. If Alphabet Inc. Class C can provide early warnings for this vast group through non-invasive methods, its commercial and social value would be immeasurable. As Francis Ho stated, "Most adults do not actively monitor this metric, but if left unaddressed, it could develop into more serious diseases." Of course, challenges also exist. This feature currently provides "trends" rather than "absolute values," and its clinical accuracy still requires long-term validation. Alphabet Inc. Class C has also made it clear that this feature "is not for diagnosing, treating, or directly measuring blood sugar." However, from the perspective of technological evolution, with the continuous advancement of sensors and AI models, "integrated glucose monitoring" is moving from science fiction to reality.